ABL Bio Secures $55 Million R&D Funding to Accelerate Grabody Platform Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2025
0mins
Source: PRnewswire
- Funding Support: ABL Bio has secured $55 million in R&D funding, including a $40 million upfront payment and a $15 million equity investment, significantly enhancing its research capabilities in the bispecific antibody sector.
- Technology Expansion: The new funding will accelerate R&D on the Grabody platform, particularly expanding into high-unmet-need areas such as obesity and muscle disorders, thereby enhancing the company's competitiveness in the biopharmaceutical market.
- Deepened Collaboration: ABL Bio's collaboration with Eli Lilly on multiple therapeutic candidates is backed by a licensing agreement valued at $2.602 billion, highlighting the strategic value of their long-term partnership.
- Clinical Progress: Several clinical projects are underway, including ABL001 (tovecimig), which has received Fast Track designation from the FDA, laying a solid foundation for the company's future market performance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
